MDSpire - Takeaway
Commentary & Perspectives

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Share

  • 1

    Semaglutide shows associations with ischaemic optic neuropathy in higher-risk populations.

  • 2

    Mixed evidence exists on GLP-1 agonists regarding ocular health.

  • 3

    Screening for diabetic retinopathy is recommended before GLP-1 RA use.

  • 4

    More nuanced safety data is needed as semaglutide use rises.

  • 5

    Neovascular AMD risk increases with longer GLP-1 RA use.

Original Source(s)

GLP-1 Eye Effects Raise Questions

  • by Kerri Miller

  • March 24, 2026

Related Content

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026

  • March 24, 2026

  • 6 min
Could NPDR Be Treated Orally?

Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema

  • March 24, 2026

  • 5 min
Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next